Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Shares Outstanding (Weighted Average) (2019 - 2025)

Allogene Therapeutics (ALLO) has disclosed Shares Outstanding (Weighted Average) for 7 consecutive years, with $220.6 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 13.25% to $220.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $220.6 million through Dec 2025, up 13.25% year-over-year, with the annual reading at $220.6 million for FY2025, 13.25% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $220.6 million in Q4 2025 for Allogene Therapeutics, down from $222.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $222.0 million in Q3 2025 to a low of $132.2 million in Q1 2021.
  • Historically, Shares Outstanding (Weighted Average) has averaged $167.1 million across 5 years, with a median of $151.9 million in 2023.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): grew 2.27% in 2023 and later increased 29.45% in 2024.
  • Year by year, Shares Outstanding (Weighted Average) stood at $135.8 million in 2021, then grew by 5.39% to $143.1 million in 2022, then grew by 9.63% to $156.9 million in 2023, then grew by 24.14% to $194.8 million in 2024, then grew by 13.25% to $220.6 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for ALLO at $220.6 million in Q4 2025, $222.0 million in Q3 2025, and $217.2 million in Q2 2025.